Ralfinamide

• UNSPSC Description:

  Ralfinamide (FCE-26742A) is an orally available Na+ blocker derived from α-aminoamide, with function of suppressing pain[1][2].

• Target Antigen:

  Sodium Channel

• Type:

  Reference compound

• Related Pathways:

  Membrane Transporter/Ion Channel

• Applications:

  Neuroscience-Neuromodulation

• Field of Research:

  Neurological Disease

• Assay Protocol:

  https://www.medchemexpress.com/ralfinamide.html

• Purity:

  99.78

• Solubility:

  DMSO : ≥ 125 mg/mL

• Smiles:

  C[C@H](NCC1=CC=C(OCC2=CC=CC=C2F)C=C1)C(N)=O

• Molecular Weight:

  302.349

• References & Citations:

  [1]Zhang SH, et al. Ralfinamide administered orally before hindpaw neurectomy or postoperatively provided long-lasting suppression of spontaneous neuropathic pain-related behavior in the rat. Pain. 2008 Oct 15;139(2):293-305.|[2]Liang X, et al. Effects of ralfinamide in models of nerve injury and chemotherapy-induced neuropathic pain. Eur J Pharmacol. 2018 Mar 15;823:27-34.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Clinical Information:

  Phase 3

• CAS Number:

  133865-88-0